Brigida R. Pinho

Porto, 4500313, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Mitophagy: an emerging therapeutic target in mitochondrial diseases.

Mitophagy: an emerging therapeutic target in mitochondrial diseases.

Journal: The Biochemical journal

Published: March 02, 2026

Inhibition of the mitochondrial pyruvate carrier attenuates the integrated stress response activation in a cellular model of Huntington's disease.

Inhibition of the mitochondrial pyruvate carrier attenuates the integrated stress response activation in a cellular model of Huntington's disease.

Journal: Molecular and cellular biochemistry

Published: January 21, 2026

Two genomes, one destiny: Mitophagy at the crossroads of inheritance and disease.

Two genomes, one destiny: Mitophagy at the crossroads of inheritance and disease.

Journal: Cell chemical biology

Published: November 13, 2025

Early motor deficits, sleep dysfunction and reduction in dopaminergic neurons in a PARK7-/- zebrafish larval model of Parkinson's disease.

Early motor deficits, sleep dysfunction and reduction in dopaminergic neurons in a PARK7-/- zebrafish larval model of Parkinson's disease.

Journal: Scientific reports

Published: October 13, 2025

Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases.

Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases.

Journal: Pharmacological reports : PR

Published: October 02, 2025

The PERK inhibitor GSK2606414 evokes developmental defects in zebrafish consistent with Wolcott-Rallison syndrome phenotypes.

The PERK inhibitor GSK2606414 evokes developmental defects in zebrafish consistent with Wolcott-Rallison syndrome phenotypes.

Journal: Pharmacological reports : PR

Published: July 28, 2025

PERK inhibition with GSK2606414 in zebrafish evokes developmental defects consistent with Wolcott-Rallison syndrome phenotypes.

PERK inhibition with GSK2606414 in zebrafish evokes developmental defects consistent with Wolcott-Rallison syndrome phenotypes.

Journal: bioRxiv : the preprint server for biology

Published: April 25, 2024

Edaravone counteracts redox and metabolic disruptions in an emerging zebrafish model of sporadic ALS.

Edaravone counteracts redox and metabolic disruptions in an emerging zebrafish model of sporadic ALS.

Journal: Free radical biology & medicine

Published: January 11, 2024

Stress response mechanisms in protein misfolding diseases: Profiling a cellular model of Huntington's disease.

Stress response mechanisms in protein misfolding diseases: Profiling a cellular model of Huntington's disease.

Journal: Archives of biochemistry and biophysics

Published: April 06, 2023

Swimming against ALS: How to model disease in zebrafish for pathophysiological and behavioral studies.

Swimming against ALS: How to model disease in zebrafish for pathophysiological and behavioral studies.

Journal: Neuroscience and biobehavioral reviews

Published: December 16, 2022

Disruptions of circadian rhythms, sleep, and stress responses in zebrafish: New infrared-based activity monitoring assays for toxicity assessment.

Disruptions of circadian rhythms, sleep, and stress responses in zebrafish: New infrared-based activity monitoring assays for toxicity assessment.

Journal: Chemosphere

Published: March 22, 2022

Automated analysis of activity, sleep, and rhythmic behaviour in various animal species with the Rtivity software.

Automated analysis of activity, sleep, and rhythmic behaviour in various animal species with the Rtivity software.

Journal: Scientific reports

Published: October 22, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026